Strategy for Identifying a Robust Metabolomic Signature Reveals the Altered Lipid Metabolism in Pituitary Adenoma
- 28 February 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (12) , 4745-4755
Abstract
Despite the well-established connection between systematic metabolic abnormalities and the pathophysiology of pituitary adenoma (PA), current metabolomic studies have reported an extremely limited number of metabolites associated with PA. Moreover, there was very little consistency in the identified metabolite signatures, resulting in a lack of robust metabolic biomarkers for the diagnosis and treatment of PA. Herein, we performed a global untargeted plasma metabolomic profiling on PA and identified a highly robust metabolomic signature based on a strategy. Specifically, this strategy is unique in (1) integrating repeated random sampling and a consensus evaluation-based feature selection algorithm and (2) evaluating the consistency of metabolomic signatures among different sample groups. This strategy demonstrated superior robustness and stronger discriminative ability compared with that of other feature selection methods including Student's t-test, partial least-squares-discriminant analysis, support vector machine recursive feature elimination, and random forest recursive feature elimination. More importantly, a highly robust metabolomic signature comprising 45 PA-specific differential metabolites was identified. Moreover, metabolite set enrichment analysis of these potential metabolic biomarkers revealed altered lipid metabolism in PA. In conclusion, our findings contribute to a better understanding of the metabolic changes in PA and may have implications for the development of diagnostic and therapeutic approaches targeting lipid metabolism in PA. We believe that the proposed strategy serves as a valuable tool for screening robust, discriminating metabolic features in the field of metabolomics.Keywords
Funding Information
- National Natural Science Foundation of China (81872798, 81971982, 82301909, 82373790, U1909208, 22220102001)
This publication has 79 references indexed in Scilit:
- The 2017 WHO classification of pituitary adenoma: overview and commentsBrain Tumor Pathology, 2018
- Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucoseDiabetologia, 2018
- Diagnosis and Treatment of Pituitary AdenomasJAMA, 2017
- Serum metabolomic pertubations among workers exposed to 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin (TCDD)Environmental and Molecular Mutagenesis, 2013
- A benchmark spike‐in data set for biomarker identification in metabolomicsJournal of Chemometrics, 2012
- Adenosine‐to‐inosine RNA editingWIREs Mechanisms of Disease, 2009
- The 2004 World health organization classification of pituitary tumors: is it clinically helpful?Acta Neuropathologica, 2005
- Comparative proteomics analysis of human pituitary adenomas: Current status and future perspectivesMass Spectrometry Reviews, 2004
- The Young BeggarJournal of Endocrinological Investigation, 1999
- Adenosine regulates the release of adrenocorticotropic hormone (ACTH) from cultured anterior pituitary cellsMolecular and Cellular Biochemistry, 1989